Trial Profile
A Phase 1, Single and Multiple Dosing Study to Evaluate Pharmacokinetics and Pharmacodynamics of ASP3325 in Patients With Chronic Kidney Disease and Hyperphosphatemia Undergoing Hemodialysis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ASP 3325 (Primary)
- Indications Hyperphosphataemia
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 31 Jul 2015 New trial record